Published in Neoplasia on May 01, 2008
Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci (2011) 5.42
Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci (2010) 3.35
Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer (2011) 3.10
Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev (2012) 2.22
The cilium secretes bioactive ectosomes. Curr Biol (2013) 1.88
Sorting it out: regulation of exosome loading. Semin Cancer Biol (2014) 1.54
Cell-to-cell miRNA transfer: from body homeostasis to therapy. Pharmacol Ther (2012) 1.27
Cathepsin B: multiple roles in cancer. Proteomics Clin Appl (2014) 1.03
The immune functions of phosphatidylserine in membranes of dying cells and microvesicles. Semin Immunopathol (2010) 1.03
Ciliary ectosomes: transmissions from the cell's antenna. Trends Cell Biol (2015) 1.02
Extracellular vesicles: communication, coercion, and conditioning. Mol Biol Cell (2013) 0.99
Emerging roles of extracellular vesicles in the adaptive response of tumour cells to microenvironmental stress. J Extracell Vesicles (2013) 0.97
Role of pHi, and proton transporters in oncogene-driven neoplastic transformation. Philos Trans R Soc Lond B Biol Sci (2014) 0.97
Acid-mediated tumor proteolysis: contribution of cysteine cathepsins. Neoplasia (2013) 0.96
Focus on Extracellular Vesicles: New Frontiers of Cell-to-Cell Communication in Cancer. Int J Mol Sci (2016) 0.95
Small but mighty: microparticles as mediators of tumor progression. Cancer Microenviron (2014) 0.86
Microvesicles as potential ovarian cancer biomarkers. Biomed Res Int (2013) 0.86
Investigating mechanisms of alkalinization for reducing primary breast tumor invasion. Biomed Res Int (2013) 0.85
Live-cell imaging of tumor proteolysis: impact of cellular and non-cellular microenvironment. Biochim Biophys Acta (2011) 0.84
Microvesicles shed by oligodendroglioma cells and rheumatoid synovial fibroblasts contain aggrecanase activity. Matrix Biol (2012) 0.82
CSE1L, a novel microvesicle membrane protein, mediates Ras-triggered microvesicle generation and metastasis of tumor cells. Mol Med (2012) 0.82
Computational analysis of the cathepsin B inhibitors activities through LR-MMPBSA binding affinity calculation based on docked complex. J Comput Chem (2009) 0.81
Microencapsulation technology by nature: Cell derived extracellular vesicles with therapeutic potential. Eur J Microbiol Immunol (Bp) (2013) 0.81
QSAR models for predicting cathepsin B inhibition by small molecules--continuous and binary QSAR models to classify cathepsin B inhibition activities of small molecules. J Mol Graph Model (2010) 0.80
Cathepsin B is up-regulated and mediates extracellular matrix degradation in trabecular meshwork cells following phagocytic challenge. PLoS One (2013) 0.80
Extracellular vesicles in prostate cancer: new future clinical strategies? Biomed Res Int (2014) 0.78
Acidic priming enhances metastatic potential of cancer cells. Pflugers Arch (2014) 0.77
Microvesicles as a potential biomarker of neoplastic diseases and their role in development and progression of neoplasm. Prz Menopauzalny (2015) 0.76
The human ovarian cancer cell line CABA I: A peculiar genetic evolution. Int J Mol Med (2016) 0.75
The biology of extracellular vesicles with focus on platelet microparticles and their role in cancer development and progression. Tumour Biol (2016) 0.75
Dinosaurs and ancient civilizations: reflections on the treatment of cancer. Neoplasia (2010) 0.75
Neoplasia: the second decade. Neoplasia (2008) 0.75
Breast cancer-derived extracellular vesicles stimulate myofibroblast differentiation and pro-angiogenic behavior of adipose stem cells. Matrix Biol (2016) 0.75
The War on Cancer rages on. Neoplasia (2009) 0.75
Multi-conformation 3D QSAR study of benzenesulfonyl-pyrazol-ester compounds and their analogs as cathepsin B inhibitors. J Mol Graph Model (2011) 0.75
Acid-mediated tumour cell invasion: a discrete modelling approach using the extended Potts model. Clin Exp Metastasis (2013) 0.75
Why do cancers have high aerobic glycolysis? Nat Rev Cancer (2004) 20.60
Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer (2006) 5.06
Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res (2006) 3.90
Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer (2005) 3.19
Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res (2005) 2.97
Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol (1990) 2.69
Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol (2002) 2.27
Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia (2006) 1.98
Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia (2007) 1.97
Cysteine cathepsins in human cancer. Biol Chem (2004) 1.91
Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J (1992) 1.79
Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin. Cancer Res (2002) 1.73
Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev (2003) 1.68
Arrest and metastasis of blood-borne tumor cells are modified by fusion of plasma membrane vesicles from highly metastatic cells. Proc Natl Acad Sci U S A (1980) 1.65
Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res (2003) 1.59
CA-074, but not its methyl ester CA-074Me, is a selective inhibitor of cathepsin B within living cells. Biol Chem (2002) 1.48
Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis (1999) 1.46
Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem (1997) 1.45
Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene (2001) 1.41
Tumor-stroma interactions: their role in the control of tumor cell invasion. Biochimie (2005) 1.33
Tumor-derived exosomes: a new source of tumor rejection antigens. Vaccine (2002) 1.33
Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res (1998) 1.33
Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass. Eur J Biochem (1999) 1.27
Imaging proteolysis by living human breast cancer cells. Neoplasia (2001) 1.27
The evolving concept of tumor microenvironments. Bioessays (2007) 1.20
Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp Cell Res (2003) 1.20
Cysteine peptidases of mammals: their biological roles and potential effects in the oral cavity and other tissues in health and disease. Crit Rev Oral Biol Med (2002) 1.14
Shedding of membrane vesicles mediates fibroblast growth factor-2 release from cells. J Biol Chem (2003) 1.13
Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene. J Cell Sci (1994) 1.13
Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clin Exp Metastasis (2000) 1.09
Human breast carcinoma cells cultured in the presence of serum shed membrane vesicles rich in gelatinolytic activities. J Submicrosc Cytol Pathol (1994) 1.08
Biologically active Fas antigen and its cognate ligand are expressed on plasma membrane-derived extracellular vesicles. Blood (1998) 1.07
Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases. FEBS Lett (1999) 1.07
Cathepsin B and human tumor progression. Biol Chem (1998) 1.04
Autocatalytic processing of recombinant human procathepsin B is a bimolecular process. FEBS Lett (1999) 1.00
Membrane vesicles shed into the extracellular medium by human breast carcinoma cells carry tumor-associated surface antigens. Clin Exp Metastasis (1995) 0.99
Ultrastructural and phenotypic characterization of CABA I, a new human ovarian cancer cell line. Oncol Res (1997) 0.94
Metastatic mouse melanoma cells release collagen-gelatin degrading metalloproteinases as components of shed membrane vesicles. Biochim Biophys Acta (1987) 0.92
Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. Biol Chem (2002) 0.90
Binding mode of CA074, a specific irreversible inhibitor, to bovine cathepsin B as determined by X-ray crystal analysis of the complex. J Biochem (1997) 0.87
Inhibitory effects of vesicles shed by human breast carcinoma cells on lymphocyte 3H-thymidine incorporation, are neutralised by anti TGF-beta antibodies. J Submicrosc Cytol Pathol (1995) 0.85
Involvement of a cathepsin B-like cysteine proteinase in platelet aggregation induced by tumor cells and their shed membrane vesicles. Clin Exp Metastasis (1986) 0.84
Plasma membrane association of cathepsin B in human prostate cancer: biochemical and immunogold electron microscopic analysis. Prostate (2001) 0.84
Selected area membrane shedding by tumor cells. Cancer Lett (1983) 0.79
Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol (2002) 2.27
Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res (2003) 2.14
Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res (2005) 2.11
Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer (2006) 2.04
Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia (2006) 1.98
Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia (2007) 1.97
Platelet-rich plasma versus focused shock waves in the treatment of jumper's knee in athletes. Am J Sports Med (2013) 1.57
Therapeutic targeting of the stem cell niche in experimental hindlimb ischemia. Nat Clin Pract Cardiovasc Med (2008) 1.47
The 1.5-A structure of Chryseobacterium meningosepticum zinc beta-lactamase in complex with the inhibitor, D-captopril. J Biol Chem (2003) 1.35
Impairment of caveolae formation and T-system disorganization in human muscular dystrophy with caveolin-3 deficiency. Am J Pathol (2002) 1.24
Role of the infections in recurrent spontaneous abortion. J Matern Fetal Neonatal Med (2011) 1.19
Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells. Cancer Res (2008) 1.19
Shedding of membrane vesicles mediates fibroblast growth factor-2 release from cells. J Biol Chem (2003) 1.13
Identification of an optimal concentration of platelet gel for promoting angiogenesis in human endothelial cells. Transfusion (2008) 1.13
Substrate-activated zinc binding of metallo-beta -lactamases: physiological importance of mononuclear enzymes. J Biol Chem (2002) 1.13
Prion protein is a component of the multimolecular signaling complex involved in T cell activation. FEBS Lett (2004) 1.12
Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood (2003) 1.07
A novel protein kinase C alpha-dependent signal to ERK1/2 activated by alphaVbeta3 integrin in osteoclasts and in Chinese hamster ovary (CHO) cells. J Cell Sci (2005) 1.06
GnRH antagonist in IVF poor-responder patients: results of a randomized trial. Reprod Biomed Online (2005) 1.04
Characterization of a new extended-spectrum beta-lactamase (TEM-87) isolated in Proteus mirabilis during an Italian survey. Antimicrob Agents Chemother (2002) 1.04
Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro. Int J Oncol (2007) 1.03
Reduced expression of the ROCK inhibitor Rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cells. PLoS One (2010) 1.01
Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res (2008) 0.99
Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol (2007) 0.95
Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocr Relat Cancer (2009) 0.95
Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res (2003) 0.95
Detrimental effects of anabolic steroids on human endothelial cells. Toxicol Lett (2007) 0.94
Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. J Biol Chem (2010) 0.94
Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost (2005) 0.93
Gorham-Stout syndrome: a monocyte-mediated cytokine propelled disease. J Bone Miner Res (2005) 0.93
Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells. Biochem J (2006) 0.92
Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer (2006) 0.92
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Mol Cancer Ther (2012) 0.92
Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147. Cancer Res (2010) 0.92
Association of GM3 with Zap-70 induced by T cell activation in plasma membrane microdomains: GM3 as a marker of microdomains in human lymphocytes. J Biol Chem (2002) 0.92
Overproduction and biochemical characterization of the Chryseobacterium meningosepticum BlaB metallo-beta-lactamase. Antimicrob Agents Chemother (2002) 0.92
Vasculogenic mimicry of human ovarian cancer cells: role of CD147. Int J Oncol (2009) 0.92
Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways. Anticancer Drugs (2006) 0.91
Association of the death-inducing signaling complex with microdomains after triggering through CD95/Fas. Evidence for caspase-8-ganglioside interaction in T cells. J Biol Chem (2002) 0.91
Vascular disrupting activity of tubulin-binding 1,5-diaryl-1H-imidazoles. J Med Chem (2009) 0.90
Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models. Int J Oncol (2011) 0.90
Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. Prostate (2008) 0.89
Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int J Cancer (2005) 0.89
Antimicrobial susceptibility of clinical isolates of Enterobacteriaceae producing complex beta-lactamase patterns including extended-spectrum enzymes. Int J Antimicrob Agents (2004) 0.88
Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells. Oncol Rep (2012) 0.87
Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. Prostate (2009) 0.87
Role of GM3-enriched microdomains in signal transduction regulation in T lymphocytes. Glycoconj J (2004) 0.87
Microvesicles as potential ovarian cancer biomarkers. Biomed Res Int (2013) 0.86
Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. Prostate (2008) 0.86
Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines. Gynecol Oncol (2010) 0.86
ERK1-2 and p38 MAPK regulate MMP/TIMP balance and function in response to thrombospondin-1 fragments in the microvascular endothelium. Life Sci (2004) 0.85
Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1. Int J Cancer (2014) 0.84
Clonal diversity and metallo-beta-lactamase production in clinical isolates of Stenotrophomonas maltophilia. Microb Drug Resist (2002) 0.84
Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells. Oncol Rep (2007) 0.84
Targeting angiogenesis with compounds from the extracellular matrix. Int J Biochem Cell Biol (2011) 0.84
Platelet gel-released supernatant modulates the angiogenic capability of human endothelial cells. Blood Transfus (2008) 0.83
Prosaposin: a new player in cell death prevention of U937 monocytic cells. Exp Cell Res (2004) 0.83
Cathepsins and pancreatic cancer: the 2012 update. Pancreatology (2012) 0.83
Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. Cancer Metastasis Rev (2007) 0.83
Kinetic properties of native and mutagenized isoforms of mitochondrial alcohol dehydrogenase III purified from Kluyveromyces lactis. Biochimie (2004) 0.82
Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule. PLoS One (2012) 0.82
Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies. Neoplasia (2012) 0.82
Association of cellular prion protein with gangliosides in plasma membrane microdomains of neural and lymphocytic cells. Neurochem Res (2002) 0.81
Osteoblast-conditioned media stimulate membrane vesicle shedding in prostate cancer cells. Int J Oncol (2006) 0.81